Connection
Robert Jotte to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications Robert Jotte has written about Programmed Cell Death 1 Receptor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.047 |
|
|
|
-
Lee SM, Hamid O, Jotte R, Zakharia Y, Medina T, Gillespie-Twardy A, Mehmi I, Chandra S, Watson G, Ward P, Chaney M, Lu H, Berndt J, O'Connor BP, Rathi K, Shaikh E, Cowey CL. Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma. Clin Cancer Res. 2025 Mar 03; 31(5):848-859.
Score: 0.047